RECRUITINGOBSERVATIONAL
Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease
About This Trial
Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain. The consequence is synthesis of altered haemoglobin S (HbS) which polymerises in red blood cell (RBC) at deoxygenated state. SCD is associated with chronic haemolytic anaemia, vaso-occlusive crisis (VOC) leading to frequent hospitalisation. The aim of the study was to to investigate whether a combination of routine laboratory biomarkers of haemolysis could be used to predict VOC development in confirmed SCD patients.
Who May Be Eligible (Plain English)
Who May Qualify:
- Sickle cell disease
Who Should NOT Join This Trial:
- \<18 years
- pregnancy
- Patient under protective guardianship or curatorship
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Sickle cell disease
Exclusion Criteria:
* \<18 years
* pregnancy
* Patient under protective guardianship or curatorship
Treatments Being Tested
BIOLOGICAL
Erythrocytic parameters and thrombin generation assay measurement
Erythrocytic parameters and thrombin generation assay measurement
Locations (1)
Rouen university Hospital
Rouen, France